LETROZOLE tablet, film coated

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

Letrozole (UNII: 7LKK855W8I) (letrozole - UNII:7LKK855W8I)

Disponible depuis:

Dr. Reddy's Laboratories Limited

DCI (Dénomination commune internationale):

Letrozole

Composition:

Letrozole 2.5 mg

Mode d'administration:

ORAL

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. . Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies (14.2, 14.3) ]. Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5) ]. Letrozole tablets may cause fetal harm when administered to a pregnant woman and the clinicl ben

Descriptif du produit:

Letrozole tablets USP, 2.5 mg are dark yellow coloured, round, biconvex, film coated tablets with ‘LET’ debossed on one side and ‘2.5’ on other side and is supplied in Bottles of 30’s count and Unit dose package of 100 (10 x 10). Bottles of 30                                                          NDC 55111-646-30 Unit dose Package of 100 (10 x 10)                          NDC 55111-646-78

Statut de autorisation:

Abbreviated New Drug Application

Résumé des caractéristiques du produit

LETROZOLE- LETROZOLE TABLET, FILM COATED
DR. REDDY'S LABORATORIES LIMITED
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LETROZOLE SAFELY AND EFFECTIVELY.
SEE FULL PRESCRIBING INFORMATION FOR LETROZOLE
LETROZOLE TABLETS USP
INITIAL U.S. APPROVAL: 1997
RECENT MAJOR CHANGES
Adjuvant Treatment of Early Breast Cancer (1.1, 2.2) 04/2010
INDICATIONS AND USAGE
Letrozole tablets are an aromatase inhibitor indicated for:
Adjuvant treatment of postmenopausal women with hormone receptor
positive early breast cancer (1.1)
Extended adjuvant treatment of postmenopausal women with early breast
cancer who have received prior standard
adjuvant tamoxifen therapy (1.2)
First and second-line treatment of postmenopausal women with hormone
receptor positive or unknown advanced
breast cancer (1.3)
DOSAGE AND ADMINISTRATION
Letrozole tablets are taken orally without regard to meals (2):
Recommended dose: 2.5.mg once daily (2.1)
Patients with cirrhosis or severe hepatic impairment: 2.5 mg every
other day (2.5, 5.3)
DOSAGE FORMS AND STRENGTHS
2.5 milligram tablets (3) (3)
CONTRAINDICATIONS
Women of premenopausal endocrine status, including pregnant women (4)
WARNINGS AND PRECAUTIONS
Decreases in bone mineral density may occur. Consider bone mineral
density monitoring (5.1)
Increases in total cholesterol may occur. Consider cholesterol
monitoring. (5.2)
Fatigue, dizziness and somnolence may occur. Exercise caution when
operating machinery (5.4)
ADVERSE REACTIONS
The most common adverse reactions (>20%) were hot flashes, arthralgia
(6.1); flushing, asthenia, edema, arthralgia,
headache, dizziness, hypercholesterolemia, sweating increased, bone
pain (6.2, 6.3); and musculoskeletal (6.4).
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT DR. REDDY’S
LABORATORIES LIMITED INC., AT 1-888-375-
3784 OR FDA AT 1-800-FDA-1088 OR www.fda.gov/medwatch
SEE 17 FOR PATIENT COUNSELING INFORMATION.
REVISED: 6/2010
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 ADJUVANT